Orlistat Market Report 2025

This Orlistat market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The orlistat market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.24 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to growing awareness of obesity-related health risks, regulatory approvals for orlistat as a prescription medication, the availability of orlistat in lower doses over-the-counter, physician recommendations, and increasing costs of obesity-related healthcare.

The orlistat market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing healthcare spending on obesity treatments, sedentary lifestyles along with unhealthy eating habits, government programs promoting weight loss and healthy living, the aging population, and prescriptions to over-the-counter shift. Major trends in the forecast period include AI-driven diet plans, telehealth services, automated devices that remind patients to take their medication and track adherence, virtual reality workouts, and digital therapeutics.

The growth of the orlistat market is expected to be driven by the increasing rates of obesity. Obesity, a condition marked by excessive body fat that adversely affects health, is commonly defined by a body mass index (BMI) of 30 or higher. The rise in obesity is linked to factors such as poor dietary habits, insufficient physical activity, and sedentary lifestyles. Orlistat aids in managing obesity by blocking the absorption of dietary fats, thus helping in weight reduction and maintenance when used alongside a reduced-calorie diet and regular exercise. For instance, the World Health Organization (WHO) reported in March 2022 that over 1 billion people worldwide were affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children. This number is expected to increase, with projections indicating that by 2025, around 167 million people, including both adults and children, will face worsening health issues due to obesity. This rising prevalence of obesity is driving demand for orlistat.

Companies in the orlistat market are focusing on developing innovative weight loss drugs to enhance personal health and comfort. These drugs are designed to help individuals reduce weight by suppressing appetite, boosting metabolism, or blocking fat absorption. For example, in November 2023, Eli Lilly and Company, a US-based pharmaceutical firm, received FDA approval for Zepbound (tirzepatide) injection, a new weight loss drug. Zepbound is unique as it is the first treatment approved to activate two incretin hormone receptors, GIP and GLP-1, targeting a fundamental cause of excess weight. It is intended for use alongside a reduced-calorie diet and increased physical activity for managing chronic weight in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) who also have at least one weight-related condition.

In August 2023, Eli Lilly and Company acquired Versanis Bio for $1.93 billion. This acquisition expands Lilly's portfolio to include Versanis' leading asset, bimagrumab, which is currently being evaluated in a Phase 2b study, both as a standalone treatment and in combination with semaglutide for overweight and obese adults. Versanis Bio Inc., based in the US, is a biotech company developing treatments for conditions related to overweight and obesity.

Major companies operating in the orlistat market are Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, Roche Holding AG, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Intas Pharmaceuticals Ltd., Lupin Pharmaceuticals Inc., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Zydus Life, Emcure Pharmaceuticals Ltd., Lannett Company Inc., Strides Pharma Science Ltd., Indoco Remedies Ltd., Wockhardt Ltd., Jubilant Life Sciences Ltd.

North America was the largest region in the orlistat market in 2024. The regions covered in the orlistat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the orlistat market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Orlistat is a drug designed to assist in weight loss by blocking the absorption of fats from food, which leads to a decrease in calorie intake. It functions by inhibiting the enzyme lipase, which is crucial for digesting dietary fats in the intestine. This medication is usually prescribed for people who are obese or overweight and is most effective when used alongside a low-fat diet and regular physical activity.

Orlistat is available in two main dosages as 120 milligrams (mg) and 60 milligrams (mg). The 120 mg dose is specifically used to support weight loss in obese individuals by preventing the absorption of dietary fats. It is generally taken three times daily with meals that contain fat. This medication can be obtained from various sources, including hospital pharmacies, online pharmacies, and retail pharmacies, and is used primarily for weight management.

The orlistat market research report is one of a series of new reports that provides orlistat market statistics, including the orlistat industry's global market size, regional shares, competitors with an orlistat market share, detailed orlistat market segments, market trends and opportunities, and any further data you may need to thrive in the orlistat industry. This orlistat market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The orlistat market consists of sales of xenical, combination supplements, and dietary aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.